Kewaunee Scientific (KEQU) reported strong FY2025 results, with adjusted EPS up 28% year-over-year and a record 38% increase in backlog, signaling a return to growth and improved business predictability. This performance, coupled with margin expansion, supports a bullish outlook for robust FY2026 revenue growth. Despite prior market pessimism, the company's enhanced operational predictability now underpins its current P/E of 15.
Kewaunee Scientific (KEQU) has demonstrated a significant operational turnaround with strong FY2025 results, signaling enhanced financial health and a clear path to future growth. Core profitability is highlighted by a 28% year-over-year increase in adjusted EPS, which strips out non-recurring items and acquisition costs. More importantly, a record 38% surge in the company's backlog provides strong visibility into the revenue pipeline for FY2026, mitigating previous market concerns about potential government budget cuts. This robust backlog, coupled with margin expansion, has fundamentally improved the company's business predictability. Consequently, while the stock trades at a P/E of 15, this valuation is now supported by a more reliable growth trajectory, suggesting a potentially undervalued position given the positive forward-looking indicators.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.80
Ticker Sentiment